Introduction: Structural and functional cardiac defects leading to inadequate tissue oxygenation is known as Heart failure (HF) which is characterized by extensive morbidity and mortality. Pathophysiology of HF involves systolic and diastolic dysfunction, neurohormonal dysregulation, and imbalance in inflammatory mediators which complicates treatment further. Cardiac resynchronization therapy (CRT) is an approach used for restoring ventricular synchrony and enhancing mechanical efficiency. This study discusses various key points of CRT and its uses in HF and discusses challenges and future implications.
Methods: An extensive review of the literature was conducted with evidence from several databases like Medline, PubMed Central, and Embase. Preference was given to articles published after 2010, but relevant articles even pre-2010 were included. Mendeley was used as a reference manager for formatting.
Results: Functional improvements and an enhanced quality of life across a diverse range of patients have been demonstrated using CRT. This has significantly impacted the mortality rates of patients with HF. This manuscript conducted a comparative analysis various hallmark clinical trials conducted in lieu of CRT, across many years (2002, 2003, 2004, 2005, 2017, 2018, 2020). All trials have noted the supremacy of CRT compared to pharmaceutical treatment or other therapeutic methods. Majority of the trial participants had an LVEF of ≤ 35%, a QRS duration of ≤ 150 ms, and were categorized as NYHA class II-IV before initiation of CRT and, posttreatment, LVEF was improved significantly. The main advantages noted were functional improvements, such as enhanced quality of life and reduced mortality.
Conclusion: There have been multiple efforts undertaken to address the challenges in CRT, which include a reduction in the rates of nonresponding patients and using alternative adjunctive therapies like defibrillators. These have been shown to improve outcomes among HF patients. Although CRT is noted to be very efficient, some challenges like technological limitations, uncertainty regarding optimal pacing, and nonresponding patients, exist. Ongoing research aims to further develop and revolutionize HF care and improve patient outcomes across the world by refining patient selections and CRT efficacy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11683778 | PMC |
http://dx.doi.org/10.1002/hsr2.70330 | DOI Listing |
Eur J Pharm Sci
January 2025
University of Ljubljana, Faculty of Pharmacy, Aškerčeva cesta 7, 1000 Ljubljana, Slovenia. Electronic address:
Dry eye disease is a multifactorial condition characterized by a loss of homeostasis of the tear film. Among the various treatment approaches, the application of ophthalmic oil-in-water nanoemulsions with incorporated anti-inflammatory drugs represents one of the most advanced approaches. However, the liquid nature of nanoemulsions limits their retention time at the ocular surface.
View Article and Find Full Text PDFJ Arrhythm
February 2025
Department of Cardiovascular Medicine, Faculty of Medical Sciences University of Fukui Fukui Japan.
Background: Accurate prediction for survival in individualized patients with cardiac resynchronization therapy with a defibrillator (CRT-D) is difficult.
Methods: We analyzed the New Japan cardiac device treatment registry (JCDTR) database to develop a survival prediction model for CRT-D recipients.
Results: Four hundred and eighty-two CRT-D recipients, at the implantation year 2018-2021, with a QRS width ≥120 ms and left ventricular ejection fraction (LVEF) ≤35% at baseline, were analyzed.
J Arrhythm
February 2025
Department of Cardiology and Clinical Examination, Faculty of Medicine Oita University Yufu Oita Japan.
Background: The prevalence rates of heart failure (HF) and hyperpolypharmacy have increased with the aging population. While a negative impact of hyperpolypharmacy on HF clinical outcomes has already been reported, the effects of hyperpolypharmacy on patients with advanced HF with reduced ejection fraction (HFrEF) undergoing cardiac resynchronization therapy (CRT) remain unclear.
Methods: We retrospectively evaluated data from 147 patients with advanced HFrEF who underwent CRT between March 2004 and June 2020.
ACS Appl Mater Interfaces
January 2025
Department of Toxicology and Sanitary Chemistry, School of Public Health, Capital Medical University, Beijing 100069, P. R. China.
Tumor metastasis is a difficult clinical problem to solve due to tumor heterogeneity and the emergence of antiapoptotic clones driven by tumor evolution. Clinical combination chemotherapy remains a standard treatment for solid metastasis tumors but with worse treatment efficiency. It is worth exploring a high-efficiency and low-side-effect therapeutic method to solve solid metastases.
View Article and Find Full Text PDFNPJ Precis Oncol
January 2025
Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Chemoradiotherapy (CRT) followed by durvalumab is standard for unresectable locally advanced non-small-cell lung cancer (LA-NSCLC). This study assesses how CRT alters the T-cell receptor (TCR) repertoire in CD8 + PD-1 + T-cells and its impact on clinical outcomes. This prospective study, conducted from November 2019 to May 2021 at three institutions in Japan, evaluated the diversity of TCR repertoire (DE50) in PD-1 + CD8 + T-cells and CD8 + T-cell phenotypes in peripheral blood before and after CRT.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!